Login to Your Account

FDA, Regulatory Challenges Blamed

Survey: Venture Capital Drying Up for U.S. Biotech

By Catherine Shaffer

Friday, October 7, 2011
According to a report by the National Venture Capital Association's MedIC Coalition, FDA regulatory challenges, reimbursement concerns and an adverse financial environment are driving venture capital (VC) investment outside the U.S. and away from major disease areas.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription